Zoledronic acid in early breast cancer: bone protection and more

Zoledronic acid is a bisphosphonate, a medicine that slows the breakdown of bone. In early breast cancer it has two roles. First, it protects bones from the thinning caused by aromatase inhibitors, ovarian suppression or early menopause. Second, in women who are postmenopausal, including those made menopausal by treatment, it has been shown to slightly lower the chance of breast cancer returning in the bones and to modestly improve survival. It is given as a short drip, commonly every six months for a few years in early breast cancer, and more often when cancer has spread to bone.

How it works

Bone is constantly broken down and rebuilt. Zoledronic acid slows the cells that break bone down. This keeps bones stronger and may make the bone environment less welcoming to cancer cells.

Who is usually considered

Postmenopausal women with early breast cancer at moderate or higher risk of recurrence, women with bone loss on hormone therapy, and people with bone metastases.

Who needs extra caution

People with significant kidney problems, low calcium or vitamin D, dental infections or planned tooth extractions. These are checked and treated before starting.

In postmenopausal women with early breast cancer, zoledronic acid gives a modest reduction in bone recurrence and a small improvement in survival, alongside protecting bones. The benefit is clearest in women who are postmenopausal and at higher risk of recurrence.

Premenopausal women benefit less

For women who still have working ovaries and are not on ovarian suppression, the recurrence benefit has not been clearly shown, though the drug may still be used to protect bone.

Side effects are usually manageable

The first-dose flu-like reaction can be unpleasant but settles. Paracetamol and fluids help. Serious problems are uncommon.

Dental care is important

Good dental health and a check before starting lower the rare risk of jaw problems.

What this page cannot tell you

It cannot tell you how much benefit you would gain. Ask your oncologist about your risk and options.

Osteonecrosis of the jaw is rare at the doses used in early breast cancer, but simple precautions lower the risk further.

Before starting

See a dentist for a check-up and complete any needed extractions or treatment of infections before the first infusion.

During treatment

Brush twice daily, floss, keep regular dental visits, and tell every dentist that you receive zoledronic acid. Avoid extractions if possible.

Warning signs

Report jaw pain, swelling, numbness, loose teeth or a sore that does not heal.

When breast cancer has spread to bone, zoledronic acid plays a different role, focused on preventing complications.

What it helps prevent

It lowers the chance of fractures, the need for radiation or surgery to bone, spinal cord compression and high blood calcium, and can ease bone pain.

Working with other treatment

Zoledronic acid for bone metastases is given alongside hormone therapy, targeted drugs or chemotherapy, and sometimes radiation to painful areas. It does not treat the cancer itself, but it protects the skeleton while other treatments control the disease, and it can reduce the need for further radiation or surgery to bone.

How it is given

Infusions are given more frequently than in early breast cancer, often every few weeks at first, sometimes spaced out later. Kidney function and calcium are checked before each dose.